@linksbridge
Linksbridge expands the capacity of NGOs, IGOs, and nonprofits to improve human lives. A social-purpose consulting and advisory firm, we help changemakers multiply their impact through creative thinking. https://linksbridge.com/
A single-dose oral treatment is raising hopes that African countries could eliminate sleeping sickness. Acoziborole is the latest in a series of improvements in the treatment of sleeping sickness made possible in large part by the work of DNDI.
www.linkedin.com/pulse/linksb...
Brazil has emerged as a key player in regional manufacturing efforts in the Americas. This week, we explore a wave of new international partnerships that aim to boost the country’s domestic cancer drug production and strengthen its diagnostics position.
www.linkedin.com/pulse/linksb...
Whether you care about access to medicines, pandemic preparedness, clinical trial results for global health products, shake-ups at major agencies and pharma companies, or African manufacturing, this week's issue has something for everyone.
www.linkedin.com/pulse/linksb...
The U.S. FDA has refused to review the company's mRNA-based flu shot—with the notable twist of CBER chief Vinay Prasad personally signing off on the decision—while Mexico is moving to expand access to Moderna's mRNA vaccine portfolio.
www.linkedin.com/pulse/linksb...
Access to health products was a key theme in this week's highlights. Samsung Biologics and CEPI are teaming up to accelerate equitable access to protein-based vaccines, BioNTech scored $25 million to develop its mRNA-based HIV vaccine for people in LMICs, and more.
www.linkedin.com/posts/linksb...
U.S. officials are trying to strongarm Gavi into removing vaccines from its portfolio that contain thimerosal, despite longstanding scientific consensus on the preservative's safety.
www.linkedin.com/pulse/linksb...
After losing its USAID funding just days before it was set to launch an African-led HIV vaccine trial, the BRILLIANT Consortium has secured alternative financial support and will begin dosing in a scaled-down trial next week.
www.linkedin.com/pulse/linksb...
CEPI is working with Valneva to find a new manufacturing partner in Asia for its chikungunya vaccine after the French pharma and Serum Institute of India scrapped their licensing deal for the shot.
www.linkedin.com/pulse/linksb...
Our first issue of 2026 covers a wide range of vaccine-related updates. CEPI has awarded Moderna a $54 million lifeline for its pandemic flu shot, WHO published a report that paints a picture of the current global vaccine ecosystem, and more.
www.linkedin.com/pulse/linksb...
As big pharma walked away from antibiotic development, small resource-constrained biotechs have stepped up—but high costs have stalled progress. This week, we explore how a public-private partnership broke the gonorrhea antibiotic deadlock.
www.linkedin.com/pulse/linksb...
While vaccine R&D plows forward, the financial and political foundations of global immunization continue to wobble.
www.linkedin.com/pulse/linksb...
Brazil's vaccine leadership is gaining momentum. The country recently approved the world's first single-dose dengue vaccine, inked international supply and tech transfer deals, and is eyeing a stronger role in PAHO Revolving Funds.
www.linkedin.com/pulse/linksb...
Image of an Incepta R&D facility.
WHO prequalification of Incepta Pharmaceuticals's generic version of the Sayana Press, a 3-month injectable contraceptive that can be self-administered, potentially gives millions more people access to a discreet, convenient, affordable option: linksbridge-8615684.hs-sites-na2.com/this-weeks-r...
🚨 New publication alert!
At the first Chikungunya Global Meeting in Panama City, stakeholders reviewed insights from recent outbreaks and discussed research priorities. Linksbridge's Katelyn Dinkel presented our chikungunya vaccine demand forecasting work and is an author of the meeting report:
Reports identify weakness in global pipeline for new antibiotics, diagnostics
The WHO says the pipeline for new antibiotics faces a "dual crisis" of scarcity and lack of innovation and that low-resource settings need simpler and faster diagnostic tests.
www.cidrap.umn.edu/a...
This week's issue has something for everyone: news about African vaccine manufacturing, updates on lenacapavir access, a look at MNCs' retreat from U.K. investments, results from a malaria vaccine clinical trial, and more.
www.linkedin.com/pulse/linksb...
A Phase 3 trial has shown that the Zabdeno/Mvabea Ebola vaccine regimen induced antibody responses in pregnant women and their infants.
www.linkedin.com/pulse/linksb...
This week's issue spotlights an impact analysis from our friends at MedAccess. The numbers are impressive: the nonprofit has reached 559 million people to date with vaccines, diagnostics and other health technologies supported by its agreements. www.linkedin.com/pulse/linksb...
In an about-face, the U.S. FDA has suspended Valneva’s chikungunya vaccine just weeks after lifting an earlier pause on use of the jab. More on this development and other pharma news important to global health in this week's issue.
www.linkedin.com/pulse/linksb...
Efforts to advance next-generation oral vaccines against polio type 1 and 3 got a boost this week with new Phase 1 trial data showing that the candidates performed similarly to their monovalent Sabin-strain comparators.
www.linkedin.com/pulse/linksb...
WHO has endorsed a new lifesaving tool in the fight against malaria. Two spatial emanator products from SC Johnson notched WHO prequalification this week, ushering in a new class of intervention for malaria vector control.
www.linkedin.com/pulse/linksb...
BARDA is culling funding for mRNA vaccine R&D—a move public health officials say will hobble the country's capacity to combat the next pandemic. More on this development and other pharma news important to global health in this week's highlights.
www.linkedin.com/pulse/linksb...
Lumbar puncture—an invasive technique with significant practical limitations—is the gold standard for diagnosing meningitis. Now, a non-invasive test may be on the horizon.
www.linkedin.com/pulse/linksb...
The early days of this week's International AIDS Society Conference on HIV Science (IAS 2025) highlighted potentially epidemic-ending interventions and an urgent need for a reimagined funding landscape.
www.linkedin.com/pulse/linksb...
Efforts to boost access to lifesaving medicines made strides this week: Novartis pledged to offer its infant-friendly antimalarial at a not-for-profit basis in malaria-endemic areas and Gilead finalized a deal with the Global Fund for its HIV PrEP drug.
www.linkedin.com/pulse/linksb...
Gavi's recent replenishment summit scored big: vaccine makers made pledges that could unlock up to $200 million in savings for Gavi-supported programs. This week's issue unpacks these commitments and other pharma news important to global health.
www.linkedin.com/pulse/linksb...
A Gilead researcher holds up a vial in an image provided by Gilead's PR apparatus.
With US FDA approval of a twice-yearly shot that prevents HIV, global health actors are mobilizing to secure access. This week's issue reviews Gilead's promises and stakeholders' doubts: linksbridge-8615684.hs-sites.com/this-weeks-r...
This week's issue covers a flurry of vaccine development news. Among the highlights: Merck moved its dengue jab to Phase 3, GSK licensed its Shigella candidate to Bharat Biotech, and Micron Biomedical launched a trial of microarray-delivered rotavirus vaccine.
www.linkedin.com/pulse/linksb...
Amid dwindling global health funding and tightening national budgets, Tanzania is making a strategic push toward pharmaceutical independence. This week's issue covers the country's plans to domestically manufacture HIV antiretrovirals and other essential medicines.
www.linkedin.com/pulse/linksb...
Amid significant funding cuts, global health stakeholders must find ways to do more with less.
That's one takeaway Linksbridge's KJ Zunigha heard in Geneva during the 78th World Health Assembly: www.linksbridge.com/resources/wh...